Literature DB >> 17416067

In vitro activity of synthetic antimicrobial peptides against Candida.

Wojciech Kamysz1, Piotr Nadolski, Anna Kedzia, Oscar Cirioni, Francesco Barchiesi, Andrea Giacometti, Giorgio Scalise, Jerzy Lukasiak, Marcin Okrój.   

Abstract

Yeast-like fungi are the most common cause of fungal infections in humans. Actually, in the age of opportunistic infections and increasing resistance, development of modern antifungal agents becomes a very important challenge. This paper describes synthesis and antimicrobial assay of four naturally occurring peptide antibiotics (aurein 1.2, citropin 1.1, temporin A, uperin 3.6) and three chemically engineered analogues actually passing clinical trials (iseganan, pexiganan, omiganan) against Candida strains isolated from patients with infections of the oral cavity or respiratory tract. The peptides were synthesized using solid-phase method and purified by high-performance liquid chromatography. Biological tests were performed using the broth microdilution method. The antifungal activity of the peptide antibiotics was compared to that of nystatin and amphotericin B. We found synthetic peptides to be generally less potent than amphotericin B or nystatin. However, some of the naturally occurring peptides still retained reasonable antifungal activities which were higher than these of iseganan, pexiganan or omiganan. We think that the naturally occurring peptide antibiotics included in our study can be a good matrix for development of novel antifungal compounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17416067

Source DB:  PubMed          Journal:  Pol J Microbiol        ISSN: 1733-1331


  5 in total

1.  Understanding interactions of Citropin 1.1 analogues with model membranes and their influence on biological activity.

Authors:  Nathalia Rodrigues de Almeida; Jonathan Catazaro; Maddeboina Krishnaiah; Yashpal Singh Chhonker; Daryl J Murry; Robert Powers; Martin Conda-Sheridan
Journal:  Peptides       Date:  2019-07-20       Impact factor: 3.750

Review 2.  Alternative approaches to antifungal therapies.

Authors:  Tarun Mehra; Martin Köberle; Christina Braunsdorf; Daniela Mailänder-Sanchez; Claudia Borelli; Martin Schaller
Journal:  Exp Dermatol       Date:  2012-10       Impact factor: 3.960

3.  Alginate oligosaccharides inhibit fungal cell growth and potentiate the activity of antifungals against Candida and Aspergillus spp.

Authors:  Anne Tøndervik; Håvard Sletta; Geir Klinkenberg; Charlotte Emanuel; Lydia C Powell; Manon F Pritchard; Saira Khan; Kieron M Craine; Edvar Onsøyen; Phil D Rye; Chris Wright; David W Thomas; Katja E Hill
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

Review 4.  Alternative Treatment Strategies for Secondary Bacterial and Fungal Infections Associated with COVID-19.

Authors:  Ritam Das; Komal Kotra; Pulkit Singh; Belinda Loh; Sebastian Leptihn; Urmi Bajpai
Journal:  Infect Dis Ther       Date:  2021-11-22

5.  Anticandidal Activity of Omiganan and Its Retro Analog Alone and in Combination with Fluconazole.

Authors:  Paulina Czechowicz; Maciej Jaśkiewicz; Damian Neubauer; Grażyna Gościniak; Wojciech Kamysz
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-02       Impact factor: 4.609

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.